Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
24 10월 2023 - 5:01AM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
therapies for rare and ultrarare diseases, today announced the
closing of its previously announced underwritten public offering of
9,833,334 shares of its common stock, including the exercise in
full by the underwriters of their option to purchase an additional
1,500,000 shares, at a price to the public of $30.00 per share,
and, to certain investors in lieu of common stock, pre-funded
warrants to purchase 1,666,722 shares of its common stock at a
purchase price of $29.999 per pre-funded warrant, which equals the
public offering price per share of the common stock less the $0.001
exercise price per share of each pre-funded warrant. The estimated
net proceeds to the company, after deducting underwriting discounts
and commissions and other offering expenses payable by the company,
were approximately $326.1 million.
J.P. Morgan, Goldman Sachs & Co. LLC, BofA Securities, and
TD Cowen acted as joint book-running managers for the offering.
The securities described above were offered by Ultragenyx
Pharmaceutical Inc. pursuant to a registration statement previously
filed with the Securities and Exchange Commission that became
automatically effective on February 12, 2021. A final prospectus
supplement and accompanying prospectus were filed with the SEC and
available for free on the SEC’s website at http://www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus related to the offering may be obtained from J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, New York 11717, by telephone at
866-803-9204, or by email at prospectus- eq_fi@jpmchase.com;
Goldman Sachs & Co. LLC, Prospectus Department, 200 West
Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile:
212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com; BofA
Securities, NC1-002-02-25, 201 North Tryon Street, Charlotte, NC
28255-0001, Attention: Prospectus Department, or by email at
dg.prospectus_requests@bofa.com; and Cowen and Company, LLC, 599
Lexington Avenue, New York, NY 10022, by email at
Prospectus_ECM@cowen.com or by telephone at (833) 297-2926.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing
novel products to patients for the treatment of serious rare and
ultrarare genetic diseases. The company has built a diverse
portfolio of approved therapies and product candidates aimed at
addressing diseases with high unmet medical need and clear biology
for treatment, for which there are typically no approved therapies
treating the underlying disease.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx's strategy is predicated upon time- and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
Contact Ultragenyx Pharmaceutical Inc.Investors &
MediaJoshua Higair@ultragenyx.com
Ultragenyx Pharmaceutical (NASDAQ:RARE)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024